• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Science & Research

  • Print
  • Share
  • E-mail

International Collaborations

graphic of world in blue and green The Office of Pediatric Therapeutics is engaged in international collaborative exchanges. The objective of these exchanges is to ensure that pediatric studies are conducted in a scientifically rigorous and ethical manner and that pediatric patients are not exposed to unnecessary (e.g., duplicative) trials.

 


 

Distribution of Pediatric Patients in Studies Submitted to FDA (2002-2007), by Country

This pie chart shows the distribution of pediatric patients in studies submitted to FDA (2002-2007) from different countries. 67% of the patients were from the U.S, 17% were from Latin America, and smaller percentages were from Netherlands, Germany, India, Gabon, Poland, South Africa, Romania, Hungary, Norway, Israel, France, and Italy.

Data Source:
Globalization Facilitates Pediatric Drug Development in the 21st Century. Julia Dunne, Lala Margaryants, M. Dianne Murphy, Ann M. Myers, Debbie Avant and William J. Rodriguez.  Drug Information Journal 2010 : 44(06)   


EMA/Japan/Canada

Pediatric legislation in the U.S. and Europe is driving pediatric product development on a global scale. In August 2007, EMA and FDA established monthly teleconferences to discuss product-specific pediatric development and topics related to product classes under the terms of Confidentiality Agreement. The objective of these exchanges are to enhance the science of pediatric trials and to avoid exposing children to unnecessary trials. This collaboration provides a robust ethical and scientific framework for pediatric studies.

Japan's PMDA joined these teleconferences in November 2009 and Health Canada in September 2010 as observers. They are now active participants in these monthly exchanges.

The monthly discussions include ethical, safety, and pediatric study feasibility issues as well as protocol discussions. The type of information exchanged includes: Pediatric Investigation Plans (PIPs); Written Requests; Pediatric Committee (PDCO) discussions; waivers and deferrals; choice of comparator and efficacy endpoints; status of ongoing pediatric studies; results of pediatric studies; safety concerns, including clinical holds; and plans for long-term safety monitoring.

FDA and EMA exchanged information on a total of 350 products and held 96 discussions on general topics (not product specific) from August 2007 through July 2014.  

 

Latin America

The purpose of FDA’s new pediatric Latin America program is to build, under our Confidentiality Commitment process, an ongoing mutually beneficial and constructive collaborative exchange of scientific information with regulators pertaining to pediatric clinical trials and product development. By exchanging information in a collaborative manner, we anticipate the development of a consortium of Latin American regulators.

Latin America is a major and growing geographical region for the conduct of pediatric pharmaceutical and medical device clinical trials. In 2011, OPT expanded their international program to include collaboration with regulatory agencies in Latin America. This new initiative has begun, in part, due to FDA’s ongoing successful exchanges with colleagues in Europe, as well as Latin America’s increasing role in pediatric medical product development . As a result, FDA receives data generated from pediatric clinical trials conducted in Latin America. Findings concerning the studies are documented in the following three publications authored by FDA’s Office of Pediatric Therapeutics.

 

 

 

 

 

Contact FDA

301-796-8659
OC-Office of Pediatric Therapeutics